Pharmacoepidemiologic Studies Should Estimate AE Background Rates – FDA

Pharmacoepidemiologic risk assessment by drug companies should include an estimate of background rates for the adverse event being studied, FDA said in its 1draft concept paper on pharmacovigilance

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet